BEDMINSTER, N.J., Oct. 8 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:
NPSP) announced today the appointment of Brian O'Callaghan as senior vice
president and chief commercial officer, effective October 15, 2007.
As a member of the NPS executive team, Mr. O'Callaghan will be
responsible for managing the company's marketing and corporate and business
development activities, including the commercial development of NPS's
late-stage products and coordination of its joint-venture partnerships with
other companies. He will report to Dr. Francois Nader, executive vice
president and chief operating officer of NPS.
Mr. O'Callaghan joins NPS from Covance, a global clinical research
organization, where he served as general manager of the cardiac safety and
IVRS business units. Previously he was North American regional business unit
head for infectious diseases and transplantation/immunology at Novartis,
president of BioPartners GmbH, and held sales and marketing positions at Merck
KGaA, Merck & Lipha Pharmaceuticals and Pfizer.
"Brian brings to NPS more than 15 years of experience in pharmaceutical
sales, marketing, business development and general management," said Dr.
Nader. "We welcome his contributions to the commercialization of our
late-stage product candidates PREOS(R) and GATTEX(TM) and to the success of
our earlier-stage corporate collaborations."
Mr. O'Callaghan has a master's degree in business administration from
Henley College and a marketing degree from Cork Regional College/Marketing
Institute of Ireland.
NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The company has drug candidates in various
stages of clinical development. Additional information is available on the
company's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. All information in this press release is as of October 8, 2007 and
we undertake no duty to update this information. A more complete description
of these risks can be found in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year-ended
December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended
June 30, 2007.
For further information:
For further information: Brandi Simpson of NPS Pharmaceuticals, Inc.,
+1-908-450-5616 Web Site: http://www.npsp.com